MSFT   181.34 (-0.03%)
FB   224.30 (-0.52%)
AMZN   2,405.73 (+0.19%)
NVDA   342.43 (+0.87%)
CGC   17.51 (-19.38%)
BABA   197.63 (-0.93%)
GE   6.53 (-3.69%)
AMD   52.12 (+0.73%)
GILD   74.91 (-0.54%)
DIS   115.47 (-1.03%)
NFLX   415.00 (+0.38%)
BAC   24.54 (-1.21%)
BA   145.68 (-2.76%)
MSFT   181.34 (-0.03%)
FB   224.30 (-0.52%)
AMZN   2,405.73 (+0.19%)
NVDA   342.43 (+0.87%)
CGC   17.51 (-19.38%)
BABA   197.63 (-0.93%)
GE   6.53 (-3.69%)
AMD   52.12 (+0.73%)
GILD   74.91 (-0.54%)
DIS   115.47 (-1.03%)
NFLX   415.00 (+0.38%)
BAC   24.54 (-1.21%)
BA   145.68 (-2.76%)
MSFT   181.34 (-0.03%)
FB   224.30 (-0.52%)
AMZN   2,405.73 (+0.19%)
NVDA   342.43 (+0.87%)
CGC   17.51 (-19.38%)
BABA   197.63 (-0.93%)
GE   6.53 (-3.69%)
AMD   52.12 (+0.73%)
GILD   74.91 (-0.54%)
DIS   115.47 (-1.03%)
NFLX   415.00 (+0.38%)
BAC   24.54 (-1.21%)
BA   145.68 (-2.76%)
MSFT   181.34 (-0.03%)
FB   224.30 (-0.52%)
AMZN   2,405.73 (+0.19%)
NVDA   342.43 (+0.87%)
CGC   17.51 (-19.38%)
BABA   197.63 (-0.93%)
GE   6.53 (-3.69%)
AMD   52.12 (+0.73%)
GILD   74.91 (-0.54%)
DIS   115.47 (-1.03%)
NFLX   415.00 (+0.38%)
BAC   24.54 (-1.21%)
BA   145.68 (-2.76%)
Log in

NASDAQ:ADPTAdaptive Biotechnologies Stock Price, Forecast & News

$38.57
-0.35 (-0.90 %)
(As of 05/29/2020 10:49 AM ET)
Add
Compare
Today's Range
$38.29
Now: $38.57
$39.17
50-Day Range
$24.95
MA: $32.97
$41.73
52-Week Range
$15.19
Now: $38.57
$55.12
Volume6,591 shs
Average Volume969,274 shs
Market Capitalization$4.89 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADPT
CUSIPN/A
CIKN/A
Phone855-466-8667

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$85.07 million
Book Value$4.35 per share

Profitability

Net Income$-68,610,000.00

Miscellaneous

Employees346
Market Cap$4.89 billion
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive ADPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.

Adaptive Biotechnologies (NASDAQ:ADPT) Frequently Asked Questions

How has Adaptive Biotechnologies' stock been impacted by COVID-19 (Coronavirus)?

Adaptive Biotechnologies' stock was trading at $21.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADPT shares have increased by 79.2% and is now trading at $38.57. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Adaptive Biotechnologies?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adaptive Biotechnologies.

When is Adaptive Biotechnologies' next earnings date?

Adaptive Biotechnologies is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Adaptive Biotechnologies.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.04. The company had revenue of $20.91 million for the quarter, compared to analysts' expectations of $21.52 million. Adaptive Biotechnologies had a negative return on equity of 22.92% and a negative net margin of 87.47%. The firm's revenue for the quarter was up 65.1% on a year-over-year basis. View Adaptive Biotechnologies' earnings history.

What price target have analysts set for ADPT?

7 Wall Street analysts have issued 1-year price targets for Adaptive Biotechnologies' shares. Their forecasts range from $32.00 to $50.00. On average, they expect Adaptive Biotechnologies' share price to reach $43.60 in the next year. This suggests a possible upside of 13.0% from the stock's current price. View analysts' price targets for Adaptive Biotechnologies.

Has Adaptive Biotechnologies been receiving favorable news coverage?

Headlines about ADPT stock have trended extremely negative this week, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Adaptive Biotechnologies earned a media sentiment score of -4.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAdaptive Biotechnologies.

Are investors shorting Adaptive Biotechnologies?

Adaptive Biotechnologies saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,210,000 shares, an increase of 7.0% from the April 30th total of 3,000,000 shares. Based on an average trading volume of 1,060,000 shares, the short-interest ratio is presently 3.0 days. Approximately 2.7% of the shares of the company are sold short. View Adaptive Biotechnologies' Current Options Chain.

Who are some of Adaptive Biotechnologies' key competitors?

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Walt Disney (DIS), Pfizer (PFE), CVS Health (CVS), Home Depot (HD) and Paypal (PYPL).

Who are Adaptive Biotechnologies' key executives?

Adaptive Biotechnologies' management team includes the following people:
  • Mr. Chad M. Robins M.B.A, Co-Founder, CEO & Chairman (Age 44)
  • Ms. Julie Rubinstein, Pres (Age 47)
  • Dr. Harlan S. Robins Ph.D., Co-Founder & Chief Scientific Officer (Age 45)
  • Mr. Christopher Carlson Ph.D., Founder
  • Mr. Chad M. Cohen, Chief Financial Officer (Age 44)

When did Adaptive Biotechnologies IPO?

(ADPT) raised $200 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

What is Adaptive Biotechnologies' stock symbol?

Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol "ADPT."

Who are Adaptive Biotechnologies' major shareholders?

Adaptive Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Viking Global Investors LP (26.43%), Matrix Capital Management Company LP (11.91%), BlackRock Inc. (3.91%), Wellington Management Group LLP (2.56%), TimesSquare Capital Management LLC (1.32%) and Capital International Investors (1.20%). Company insiders that own Adaptive Biotechnologies stock include Andris A Zoltners, Chad M Cohen, Chad M Robins, Charles Sang, Eric Dobmeier, Harlan S Robins, Julie Rubinstein, Lance Baldo, Nancy Louise Hill, Robert Hershberg, Sharon Benzeno, Stacy L Taylor and Viking Global Performance Llc. View institutional ownership trends for Adaptive Biotechnologies.

Which institutional investors are selling Adaptive Biotechnologies stock?

ADPT stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Matrix Capital Management Company LP, Blair William & Co. IL, Invesco Ltd., HighTower Advisors LLC, Redmile Group LLC, Clarius Group LLC, and Fred Alger Management LLC. Company insiders that have sold Adaptive Biotechnologies company stock in the last year include Andris A Zoltners, Chad M Cohen, Chad M Robins, Charles Sang, Eric Dobmeier, Harlan S Robins, Julie Rubinstein, Lance Baldo, Nancy Louise Hill, Robert Hershberg, Sharon Benzeno, Stacy L Taylor, and Viking Global Performance Llc. View insider buying and selling activity for Adaptive Biotechnologies.

Which institutional investors are buying Adaptive Biotechnologies stock?

ADPT stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Capital International Investors, Wells Fargo & Company MN, Frontier Capital Management Co. LLC, State Street Corp, Massachusetts Financial Services Co. MA, and Deutsche Bank AG. Company insiders that have bought Adaptive Biotechnologies stock in the last two years include Chad M Cohen, Nancy Louise Hill, and Viking Global Performance Llc. View insider buying and selling activity for Adaptive Biotechnologies.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adaptive Biotechnologies' stock price today?

One share of ADPT stock can currently be purchased for approximately $38.57.

How big of a company is Adaptive Biotechnologies?

Adaptive Biotechnologies has a market capitalization of $4.89 billion and generates $85.07 million in revenue each year. The company earns $-68,610,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Adaptive Biotechnologies employs 346 workers across the globe.

What is Adaptive Biotechnologies' official website?

The official website for Adaptive Biotechnologies is www.adaptivebiotech.com.

How can I contact Adaptive Biotechnologies?

Adaptive Biotechnologies' mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The company can be reached via phone at 855-466-8667 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.